{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:27Z","timestamp":1787020707475,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100021336","name":"Office of Minority Health","doi-asserted-by":"publisher","award":["CPIMP171157"],"award-info":[{"award-number":["CPIMP171157"]}],"id":[{"id":"10.13039\/100021336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01201-3","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T23:48:33Z","timestamp":1744415313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of psychostimulant use on office based buprenorphine treatment retention"],"prefix":"10.1186","volume":"22","author":[{"given":"Ryan","family":"Edgerton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rebeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"MacMaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Ginn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeraj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Lyle","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"1201_CR1","unstructured":"Center for Disease Control and Prevention (CDC). HIV Surveillance Report 2022. 2023; Available from: https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html"},{"key":"1201_CR2","unstructured":"Paulozzi LJ, Jones CM, Mack KA, Rudd RA. Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999\u20132008 [Internet]. [cited 2025 Mar 11]. Available from: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6043a4.htm"},{"key":"1201_CR3","doi-asserted-by":"crossref","unstructured":"Mattson CL. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths \u2014 United States, 2013\u20132019. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2025 Mar 11];70. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7006a4.htm","DOI":"10.15585\/mmwr.mm7006a4"},{"key":"1201_CR4","doi-asserted-by":"publisher","first-page":"101184","DOI":"10.1016\/j.pmedr.2020.101184","volume":"20","author":"R Lyle Cooper","year":"2020","unstructured":"Lyle Cooper R, Thompson J, Edgerton R, Watson J, MacMaster SA, Kalliny M, et al. Modeling dynamics of fatal opioid overdose by state and across time. Prev Med Rep. 2020;20:101184.","journal-title":"Prev Med Rep"},{"issue":"4","key":"1201_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350.","journal-title":"Curr Opin Psychiatry"},{"key":"1201_CR6","doi-asserted-by":"publisher","first-page":"109310","DOI":"10.1016\/j.drugalcdep.2022.109310","volume":"232","author":"SC Warfield","year":"2022","unstructured":"Warfield SC, Bharat C, Bossarte RM, DePhilippis D, Farrell M, Hoover M, et al. Trends in comorbid opioid and stimulant use disorders among veterans receiving care from the veterans health administration, 2005\u20132019. Drug Alcohol Depend. 2022;232:109310.","journal-title":"Drug Alcohol Depend"},{"key":"1201_CR7","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell J. Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants \u2014 24 States and the District of Columbia, January\u2013June 2019. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [cited 2025 Mar 11];69. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6935a1.htm","DOI":"10.15585\/mmwr.mm6935a1"},{"issue":"5","key":"1201_CR8","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/add.14878","volume":"115","author":"B Hoots","year":"2020","unstructured":"Hoots B, Vivolo-Kantor A, Seth P. The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the united States. Addict Abingdon Engl. 2020;115(5):946\u201358.","journal-title":"Addict Abingdon Engl"},{"key":"1201_CR9","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 NAtional Survey on Drug Use and Health. 2018."},{"issue":"2","key":"1201_CR10","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","volume":"70","author":"JH Jaffe","year":"2003","unstructured":"Jaffe JH, O\u2019Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the united States. Drug Alcohol Depend. 2003;70(2):S3\u201311.","journal-title":"Drug Alcohol Depend"},{"key":"1201_CR11","doi-asserted-by":"publisher","first-page":"100133","DOI":"10.1016\/j.dadr.2023.100133","volume":"6","author":"C Heidbreder","year":"2023","unstructured":"Heidbreder C, Fudala PJ, Greenwald MK. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug Alcohol Depend Rep. 2023;6:100133.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"1","key":"1201_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","volume":"20","author":"DL Louie","year":"2019","unstructured":"Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157.","journal-title":"BMC Fam Pract"},{"issue":"2","key":"1201_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","volume":"14","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95\u20138.","journal-title":"J Addict Med"},{"issue":"1","key":"1201_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13722-022-00342-1","volume":"17","author":"J Carter","year":"2022","unstructured":"Carter J, Li Z, Chen H, Greiner M, Bush C, Bhattacharya D, et al. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study. Addict Sci Clin Pract. 2022;17(1):60.","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"1201_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/00952990.2023.2251653","volume":"49","author":"RL Cooper","year":"2023","unstructured":"Cooper RL, Edgerton RD, Watson J, Conley N, Agee WA, Wilus DM, et al. Meta-analysis of primary care delivered buprenorphine treatment retention outcomes. Am J Drug Alcohol Abuse. 2023;49(6):756\u201365.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"1201_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11606-020-06201-6","volume":"36","author":"D Motavalli","year":"2021","unstructured":"Motavalli D, Taylor JL, Childs E, Valente PK, Salhaney P, Olson J, et al. Health is on the back burner: multilevel barriers and facilitators to primary care among people who inject drugs. J Gen Intern Med. 2021;36(1):129\u201337.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"1201_CR17","first-page":"605","volume":"55","author":"O Heidari","year":"2023","unstructured":"Heidari O, Tormohlen K, Dangerfield DT, Tobin KE, Farley JE, Aronowitz SV. Barriers and facilitators to primary care engagement for people who inject drugs: A systematic review. J Nurs Scholarsh Off Publ Sigma Theta Tau Int Honor Soc Nurs. 2023;55(3):605\u201322.","journal-title":"J Nurs Scholarsh Off Publ Sigma Theta Tau Int Honor Soc Nurs"},{"issue":"6","key":"1201_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/add.14892","volume":"115","author":"D Lewer","year":"2020","unstructured":"Lewer D, Freer J, King E, Larney S, Degenhardt L, Tweed EJ, et al. Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis. Addict Abingdon Engl. 2020;115(6):1011\u201323.","journal-title":"Addict Abingdon Engl"},{"issue":"9","key":"1201_CR19","first-page":"CD011117","volume":"2022","author":"S Nielsen","year":"2022","unstructured":"Nielsen S, Tse WC, Larance B. Opioid agonist treatment for people who are dependent on pharmaceutical opioids. Cochrane Database Syst Rev. 2022;2022(9):CD011117.","journal-title":"Cochrane Database Syst Rev"},{"key":"1201_CR20","doi-asserted-by":"publisher","first-page":"110911","DOI":"10.1016\/j.drugalcdep.2023.110911","volume":"250","author":"JI Tsui","year":"2023","unstructured":"Tsui JI, Whitney BM, Korthuis PT, Chan B, Pho MT, Jenkins WD, et al. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs. Drug Alcohol Depend. 2023;250:110911.","journal-title":"Drug Alcohol Depend"},{"key":"1201_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jsat.2019.10.005","volume":"109","author":"JI Tsui","year":"2020","unstructured":"Tsui JI, Mayfield J, Speaker EC, Yakup S, Ries R, Funai H, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abuse Treat. 2020;109:80\u20135.","journal-title":"J Subst Abuse Treat"},{"key":"1201_CR22","doi-asserted-by":"publisher","first-page":"108329","DOI":"10.1016\/j.jsat.2021.108329","volume":"126","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Williams AR, Saloner B, Cerd\u00e1 M. Who stays in medication treatment for opioid use disorder? A National study of outpatient specialty treatment settings. J Subst Abuse Treat. 2021;126:108329.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"1201_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/ajad.13268","volume":"31","author":"MM Sweeney","year":"2022","unstructured":"Sweeney MM, Prichett L, Fingerhood MI, Antoine D, Umbricht A, Dunn KE, et al. Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting. Am J Addict. 2022;31(3):256\u201360.","journal-title":"Am J Addict"},{"key":"1201_CR24","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substacne Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. 2022."},{"issue":"3","key":"1201_CR25","doi-asserted-by":"publisher","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","volume":"5","author":"PM Mauro","year":"2022","unstructured":"Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. JAMA Netw Open. 2022;5(3):e223821.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"1201_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","volume":"172","author":"SE Hadland","year":"2018","unstructured":"Hadland SE, Bagley SM, Rodean J, Silverstein M, Levy S, Larochelle MR, et al. Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatr. 2018;172(11):1029\u201337.","journal-title":"JAMA Pediatr"},{"issue":"2","key":"1201_CR27","doi-asserted-by":"publisher","first-page":"e1920843","DOI":"10.1001\/jamanetworkopen.2019.20843","volume":"3","author":"AS Huhn","year":"2020","unstructured":"Huhn AS, Hobelmann JG, Strickland JC, Oyler GA, Bergeria CL, Umbricht A, et al. Differences in availability and use of medications for opioid use disorder in residential treatment settings in the united States. JAMA Netw Open. 2020;3(2):e1920843.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1201_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.7326\/M19-3975","volume":"173","author":"EE McGinty","year":"2020","unstructured":"McGinty EE, Stone EM, Kennedy-Hendricks A, Bachhuber MA, Barry CL. Medication for opioid use disorder: A National survey of primary care physicians. Ann Intern Med. 2020;173(2):160\u20132.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1201_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","volume":"38","author":"R Mojtabai","year":"2019","unstructured":"Mojtabai R, Mauro C, Wall MM, Barry CL, Olfson M. Medication treatment for opioid use disorders in substance use treatment facilities. Health Aff (Millwood). 2019;38(1):14\u201323.","journal-title":"Health Aff (Millwood)"},{"key":"1201_CR30","doi-asserted-by":"crossref","unstructured":"Dowell D. Treatment for Opioid Use Disorder: Population Estimates \u2014 United States, 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2024 [cited 2025 Mar 11];73. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/73\/wr\/mm7325a1.htm","DOI":"10.15585\/mmwr.mm7325a1"},{"issue":"1","key":"1201_CR31","first-page":"193","volume":"92","author":"MS Haddad","year":"2015","unstructured":"Haddad MS, Zelenev A, Altice FL. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. J Urban Health Bull N Y Acad Med. 2015;92(1):193\u2013213.","journal-title":"J Urban Health Bull N Y Acad Med"},{"issue":"1","key":"1201_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13722-022-00288-4","volume":"17","author":"A Cheng","year":"2022","unstructured":"Cheng A, Badolato R, Segoshi A, McDonald R, Malone M, Vasudevan K, et al. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study. Addict Sci Clin Pract. 2022;17(1):4.","journal-title":"Addict Sci Clin Pract"},{"key":"1201_CR33","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"issue":"1","key":"1201_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13722-021-00266-2","volume":"16","author":"MC Frost","year":"2021","unstructured":"Frost MC, Lampert H, Tsui JI, Iles-Shih MD, Williams EC. The impact of methamphetamine\/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review. Addict Sci Clin Pract. 2021;16(1):62.","journal-title":"Addict Sci Clin Pract"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01201-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T23:48:41Z","timestamp":1744415321000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01201-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01201-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5663844\/v1","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was approved by the Meharry Medical College Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}